IsoPlexis, Lonza partner on cell therapy manufacturing

By The Science Advisory Board staff writers

August 20, 2020 -- IsoPlexis and Lonza have partnered to advance automated cell therapy manufacturing.

The partnership will utilize IsoPlexis' IsoLight automated cell manufacturing platform and Lonza's Cocoon automated cell therapy manufacturing solution to perform end-to-end automation. Notably, IsoLight will perform functional proteomics analysis on cell therapy products created by Cocoon.

IsoLight provides functional characterization of cell therapy products for correlative functional potency, according to IsoPlexis. Meanwhile, Cocoon enables centralized and decentralized manufacturing of novel cell therapies, noted Lonza.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.